Vestronidase Alfa-vjbk Injection (MEPSEVII® )

Mepsevii (vestronidase alfa‑vjbk) is covered only for the FDA‑approved indication MPS VII (Sly syndrome) and is excluded for non‑FDA indications; approvals are limited to 12 months with dosing up to 4 mg/kg IV no more frequently than every 2 weeks. Coverage requires documented deficient beta‑glucuronidase activity (leukocytes, fibroblasts, or serum) or a GUSB gene mutation and that the drug be prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder/lysosomal storage disorder specialist, with documentation of dosing and infusion interval.

"Mepsevii is indicated for the treatment of individuals with mucopolysaccharidosis type VII (MPS VII; Sly syndrome)."

Sign up to see full coverage criteria, indications, and limitations.